Live tape
Top 8, mentions 7d5,877META1,590 mentions▲ +0.06GOOGL1,136 mentions▲ +0.03NVDA768 mentions▲ +0.09TSLA516 mentions▲ +0.05MSFT513 mentions▲ +0.06AMZN472 mentions▲ +0.04SPY465 mentions▲ +0.03AAPL417 mentions▲ +0.06

Equity · Healthcare

CCCC

NASDAQ

C4 Therapeutics, Inc.

$3.12 +4.00% vs prior close Finazon · prior-day close, indicative (IEX-derived, not the official close) · Sep 28, 2026
Price · Chart
Our own end-of-day closes 61 sessions
$4.5 $2.5 2 Jul 28 Sep

The line runs $4.31 on 2 July through $3.12 on 28 September, on a scale from $2.5 to $4.5. Days the market did not trade hold the previous close, flat.

Track this symbol on TradingView

The chart above plots the price of CCCC over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 61 sessions over that window: $4.31 on 2 July 2026 through $3.12 on 28 September 2026.

Market cap $383.8M
52-week range $1.70 – $4.66
Avg volume 135.7K

Finazon · prior-day close, indicative (IEX-derived, not the official close) · valuation computed from SEC EDGAR filings · as of Sep 28, 2026

CCCC insider trades

SEC Form 4 · last 90 days · newest Form 4 filing 18 Sep 2026
Open-market buys 0
Open-market sells 0
Non-trade filings 4

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value
18 Sep 2026 Adams Kendra Chief Financial Officer Option exercise 6,250
18 Sep 2026 Adams Kendra Chief Financial Officer Tax withheld 2,775 $9K
10 Jul 2026 REYNO LEONARD Chief Medical Officer Option exercise 15,325
10 Jul 2026 REYNO LEONARD Chief Medical Officer Tax withheld 7,397 $30K

CCCC reported financials

SEC EDGAR XBRL

CCCC reported revenue of $35.9M for the fiscal year ended 31 Dec 2025. Net income over the same period was −$105.0M.

Figure Reported Period
Revenue $35.9M 31 Dec 2025 fiscal year
Net income −$105.0M 31 Dec 2025 fiscal year
Diluted EPS −$1.27 31 Dec 2025 fiscal year
Total assets $359.4M 30 Jun 2026 at period end
Total equity $247.3M 30 Jun 2026 at period end

Source: SEC EDGAR XBRL company facts · latest period ended 30 Jun 2026

CCCC earnings

SEC EDGAR
Date Period EPS Revenue
30 Jun 2026 Q2 2026 $-0.18 $7M
31 Mar 2026 Q1 2026 $-0.20 $6M
31 Dec 2025 FY 2025 $-1.27 $36M
30 Sep 2025 Q3 2025 $-0.44 $11M
30 Jun 2025 Q2 2025 $-0.37 $6M
31 Mar 2025 Q1 2025 $-0.37 $7M
31 Dec 2024 FY 2024 $-1.52 $36M
30 Sep 2024 Q1 2023 $-0.35 $15M

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

CCCC institutional holders

SEC Form 13F

8 of the 45 institutional funds we track reported a CCCC position for the quarter ended 30 Jun 2026 — a combined $54.2M; the latest of those filings landed 02 Sep 2026.

Fund Action Shares Value
Citadel Advisors Added +66.8% shares 4,187,580 $19.6M
Two Sigma Investments Held (±25%) +14.3% shares 3,469,707 $16.2M
D. E. Shaw & Co. Added +64.2% shares 1,740,989 $8.1M
Renaissance Technologies Trimmed −51.7% shares 1,189,828 $5.6M
Man Group Added +59.3% shares 408,648 $1.9M
Marshall Wace Added +46.0% shares 227,003 $1.1M
Millennium Management Trimmed −84.5% shares 215,386 $1.0M
Point72 Asset Management Held (±25%) +2.9% shares 173,965 $812K

Source: SEC EDGAR 13F filings

CCCC fails-to-deliver

SEC CNS data

On 31 Aug 2026, 3,894 shares of CCCC failed to deliver (about $15K).

Settlement date Shares failed Notional % of shares out
31 Aug 2026 3,894 $15K 0.003%
27 Aug 2026 81 $343 <0.001%
25 Aug 2026 26 $107 <0.001%

Source: SEC fails-to-deliver (CNS) data